vTv Therapeutics(NASDAQ) VTVT

vTv Therapeutics makes oral pills for people living with diabetes. These medicines help patients manage their blood sugar alongside standard insulin treatments. The company focuses on making daily health management simpler for those with chronic metabolic diseases.

The Pipeline for Diabetes Care

• Cadisegliatin: Liver-selective glucokinase activator, an enzyme that senses blood sugar, designed to reduce low-glucose events in Type 1 diabetes.
• TTP273: Oral hormone-mimicking drug meant to control blood sugar spikes after meals for patients with cystic fibrosis-related diabetes.
• HPP737: Anti-inflammatory treatment that blocks an enzyme called PDE4 to help with skin conditions like psoriasis.
• Azeliragon: Medicine that blocks specific cell receptors to potentially treat inflammatory lung diseases and various cancers.

Strategic Moves and Partnerships

• Closed an $80 million private placement in September 2025 to support its primary clinical trials.
• Amended a global license agreement with Newsoara BioPharma in January 2026 for its anti-inflammatory program.
• Started a Phase 2 trial in the Middle East in December 2025 with partner G42 Investments.
• Maintains a license agreement with Novo Nordisk for the discovery and development of its core diabetes technology.

What Makes vTv Different?

vTv holds a Breakthrough Therapy designation from the Food and Drug Administration (FDA) for its lead diabetes candidate. Its technology focuses on activating enzymes specifically in the liver to avoid side effects in other parts of the body.

Money Matters and Market Figures

• Revenue reached $0 in Q4 2025, down 100% from $17,000 in Q4 2024.
• Operating income was -$7.9 million in Q4 2025, a deepened loss of 61.2% year-over-year.
• Net income reached -$7.1 million in Q4 2025, which worsened by 96.4% from the previous year.
• Free cash flow was -$9.3 million in Q4 2025, down 91.7% from Q4 2024.
• Market capitalization grew to $336.9 million in Q4 2025, up 322.7% from the previous year.

The Path Ahead

vTv has evolved into a late-stage developer focused on oral alternatives for diabetes management. The company maintains its operations through strategic licensing deals and equity financing as it moves toward final clinical testing.